Retinoblastoma Biomarker Study
| Status: | Completed |
|---|---|
| Conditions: | Skin Cancer, Cancer, Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 8 - 80 |
| Updated: | 4/6/2019 |
| Start Date: | November 17, 1993 |
A series of 1,729 retinoblastoma (RB) patients were identified from medical records at
hospital centers in Boston (1937-84) and New York (1914-84). The study cohort consists of the
1,604 patients who survived at least 1 year after RB diagnosis. Information was obtained from
medical records and interviews conducted in 1987 and 1993. RB patients had a 30-fold excess
risk of another cancer, and a 50% chance of developing a cancer if they survived to 50 years
of age. Blood samples have been collected from 481 patients, and studies are underway to
determine if certain mutations in the RB1 genes are associated with increased or decreased
penetrance or with increased risk of subsequent cancer development. The study population in
New York is being expanded currently to include patients treated since 1984, and their
medical records are being abstracted. Blood samples will be collected from the newly
identified patients who are returning to New York Hospital for a followup RB exam....
hospital centers in Boston (1937-84) and New York (1914-84). The study cohort consists of the
1,604 patients who survived at least 1 year after RB diagnosis. Information was obtained from
medical records and interviews conducted in 1987 and 1993. RB patients had a 30-fold excess
risk of another cancer, and a 50% chance of developing a cancer if they survived to 50 years
of age. Blood samples have been collected from 481 patients, and studies are underway to
determine if certain mutations in the RB1 genes are associated with increased or decreased
penetrance or with increased risk of subsequent cancer development. The study population in
New York is being expanded currently to include patients treated since 1984, and their
medical records are being abstracted. Blood samples will be collected from the newly
identified patients who are returning to New York Hospital for a followup RB exam....
A series of 1,729 retinoblastoma (RB) patients were identified from medical records at
hospital centers in Boston (1937-84) and New York (1914-84). The study cohort consists of the
1,604 patients who survived at least 1 year after RB diagnosis. Information was obtained from
medical records and interviews conducted in 1987 and 1993. RB patients had a 30-fold excess
risk of another cancer, and a 50% chance of developing a cancer if they survived to 50 years
of age. Blood samples have been collected from 481 patients, and studies are underway to
determine if certain mutations in the RB1 genes are associated with increased or decreased
penetrance or with increased risk of subsequent cancer development. The study population in
New York is being expanded currently to include patients treated since 1984, and their
medical records are being abstracted. Blood samples will be collected from the newly
identified patients who are returning to New York Hospital for a followup RB exam.
hospital centers in Boston (1937-84) and New York (1914-84). The study cohort consists of the
1,604 patients who survived at least 1 year after RB diagnosis. Information was obtained from
medical records and interviews conducted in 1987 and 1993. RB patients had a 30-fold excess
risk of another cancer, and a 50% chance of developing a cancer if they survived to 50 years
of age. Blood samples have been collected from 481 patients, and studies are underway to
determine if certain mutations in the RB1 genes are associated with increased or decreased
penetrance or with increased risk of subsequent cancer development. The study population in
New York is being expanded currently to include patients treated since 1984, and their
medical records are being abstracted. Blood samples will be collected from the newly
identified patients who are returning to New York Hospital for a followup RB exam.
- INCLUSION CRITERIA:
Children treated for retroblastoma over the past 30-plus years.
We found this trial at
1
site
9609 Medical Center Drive
Bethesda, Maryland 20892
Bethesda, Maryland 20892
1-800-422-6237
National Cancer Institute , 9000 Rockville Pike The National Cancer Institute (NCI) is part of...
Click here to add this to my saved trials
